91桃色

The human gut microbiota, a complex community of trillions of microorganisms including bacteria, fungi, viruses, and archaea, plays a crucial role in maintaining human health. Over the past few decades, research has revealed that the gut microbiota not only influences digestive health but also modulates systemic immune responses, metabolism, and even behavior. One of the most significant discoveries in recent years is the impact of gut microbiota on inflammation, which, in turn, plays a pivotal role in the development and progression of cancer. Chronic inflammation is recognized as a hallmark of cancer, and the gut microbiota, through its interactions with the immune system, can either promote or mitigate inflammation, thus influencing tumor growth, metastasis, and response to therapy. This article explores the mechanisms through which the gut microbiota modulates inflammation and its subsequent effects on cancer progression [1].

Description

Gut microbiota and inflammation

The gut microbiota is intimately linked with the host immune system, particularly the gastrointestinal tract's immune cells. A healthy gut microbiota helps maintain immune homeostasis by promoting the development of immune cells such as regulatory T cells (Tregs) and tolerogenic dendritic cells, which control inflammation. However, dysbiosis, an imbalance in the microbiota, can lead to the activation of pro-inflammatory pathways that have been implicated in various diseases, including cancer [2].

Immune system activation: The gut microbiota influences the innate and adaptive immune responses. In a balanced microbiome, commensal bacteria stimulate the production of anti-inflammatory cytokines, promoting immune tolerance and preventing overactive immune responses. However, an imbalance in the microbiota (dysbiosis) can lead to the activation of inflammatory signaling pathways, such as the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the mitogen-activated protein kinase (MAPK) pathways [3]. These pathways increase the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), which are known to promote cancer initiation and progression.

Microbial metabolites and inflammation: The gut microbiota produces a wide range of metabolites, some of which have potent anti-inflammatory or pro-inflammatory effects. Short-chain fatty acids (SCFAs), such as butyrate, propionate, and acetate, are produced during the fermentation of dietary fiber by gut bacteria. These SCFAs play a crucial role in reducing inflammation by promoting the differentiation of Tregs and inhibiting the production of pro-inflammatory cytokines. In contrast, certain gut bacteria may produce metabolites, such as bile acids, that can exacerbate inflammation and support tumorigenesis [4].

Gut barrier integrity: A healthy gut microbiota helps maintain the integrity of the intestinal epithelial barrier, preventing the translocation of harmful pathogens and inflammatory mediators into the bloodstream. However, dysbiosis can impair the gut barrier function, leading to "leaky gut," where inflammatory cytokines and microbial products enter the systemic circulation. This condition can cause chronic low-grade inflammation, contributing to systemic inflammation and increasing the risk of cancer [5].

Gut microbiota and cancer progression

The interaction between the gut microbiota and the host immune system has a direct impact on cancer progression. Dysbiosis-induced inflammation has been shown to promote the initiation, growth, and metastasis of various cancers, including colorectal, liver, and breast cancers. The role of gut microbiota in cancer progression is multifaceted, involving immune modulation, metabolic changes, and the production of carcinogenic metabolites.

Tumor initiation and promotion: Chronic inflammation is a key driver of tumor initiation. Inflammatory cytokines, such as IL-6 and TNF-α, can activate signaling pathways that lead to the transformation of normal cells into cancerous ones. For example, the NF-κB pathway, which is activated during inflammation, is frequently dysregulated in cancer cells, leading to their uncontrolled proliferation [6]. Additionally, microbiota-induced inflammation can create a pro-tumorigenic microenvironment by increasing the production of reactive oxygen species (ROS) that damage DNA and promote mutations.

Tumor microenvironment: The gut microbiota influences the tumor microenvironment (TME), a complex network of cancer cells, immune cells, blood vessels, and extracellular matrix components that support tumor growth. Microbial-induced inflammation can recruit inflammatory immune cells, such as macrophages and neutrophils, into the TME, where they secrete pro-inflammatory cytokines that stimulate tumor cell proliferation and metastasis. Furthermore, certain gut bacteria, like Fusobacterium nucleatum, have been found to directly interact with cancer cells and contribute to their growth, especially in colorectal cancer.

Metastasis: Chronic gut inflammation can enhance the ability of cancer cells to invade and metastasize. Pro-inflammatory cytokines and immune cells in the TME can promote angiogenesis, the formation of new blood vessels, which provides the tumor with a sufficient blood supply to grow and metastasize. Dysbiosis has also been linked to increased epithelial-mesenchymal transition (EMT), a process that enables cancer cells to detach from the primary tumor and invade distant organs [7].

Gut microbiota and immune evasion: The gut microbiota can influence the immune response to tumors. Certain microbial species are known to modulate the immune system, either promoting anti-tumor immunity or helping tumors evade immune surveillance. For instance, some gut bacteria can stimulate the activation of cytotoxic T cells and natural killer (NK) cells, leading to tumor cell destruction. On the other hand, dysbiosis may increase the population of immune suppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which inhibit the immune system’s ability to detect and destroy cancer cells.

Gut microbiota and cancer therapy

The gut microbiota also influences the response to cancer therapies, including chemotherapy, immunotherapy, and targeted therapies. Recent studies suggest that the composition of the gut microbiota can alter the effectiveness of these treatments [8].

Chemotherapy: Gut bacteria play a role in modulating the pharmacokinetics and toxicity of chemotherapy drugs. Some bacterial species can metabolize chemotherapeutic agents, influencing their effectiveness or causing unwanted side effects. For example, gut microbiota can activate or inactivate specific drugs, thus altering their therapeutic potential.

Immunotherapy: The gut microbiota has a profound impact on the effectiveness of immunotherapy, particularly immune checkpoint inhibitors. Studies have shown that a diverse and balanced gut microbiota can enhance the anti-tumor response to immunotherapy by promoting the activation of T cells and other immune cells. Conversely, dysbiosis can impair the response to immunotherapy, highlighting the importance of the gut microbiota in immunotherapeutic outcomes [9].

Targeted therapies: Targeted therapies, which aim to inhibit specific molecular pathways driving cancer growth, can also be influenced by the gut microbiota. Microbial metabolites and immune modulators can either enhance or diminish the effectiveness of these treatments, making the microbiota an important factor in personalized cancer therapy [10].

Conclusion

The gut microbiota plays a central role in modulating inflammation, which is a key driver of cancer progression. Dysbiosis-induced inflammation can promote tumor initiation, growth, metastasis, and immune evasion, while a balanced microbiome helps maintain immune homeostasis and may protect against cancer. Additionally, the gut microbiota can significantly impact the efficacy of cancer therapies, including chemotherapy, immunotherapy, and targeted treatments. Understanding the intricate relationship between the gut microbiota, inflammation, and cancer is crucial for developing novel therapeutic strategies. By manipulating the gut microbiome through diet, probiotics, or antibiotics, it may be possible to influence the inflammatory environment and improve cancer treatment outcomes. As research in this area continues to evolve, the gut microbiota could become an important target for cancer prevention and therapy, offering new avenues for enhancing patient care.

Acknowledgement

None

Conflict of Interest

None

1. Chen MJ, Shih SC, Wang HY, Lin CC, Liu CY, et al. (2013) . Evid-Based Complement Altern Med 270906.

, ,

2. Papademetrio DL, Lompard铆a SL, Simunovich T, Costantino S, Mihalez CY, et al. (2015) . Targ Oncol 1: 183-195.

, ,

3. Rzepecka-Stojko A, Kaba艂a-Dzik A, Mo藕dzierz A, Kubina R, Wojtyczka RD, et al. (2015) . Molecules 20: 9242-9262.

, ,

4. Omene C, Wu J, Frenkel K (2011) Invest New Drugs 30: 1279-1288.

, ,

5. Lonardo E, Hermann P, Heeschen C (2010) . Mol Oncol 4: 431-442.

, ,

6. Osterman CJ, Lynch J, Leaf P, Gonda A, Ferguson Bennit HR, et al. (2015) . Plos One 10: e0132845.

, ,

7. Tsai C, Hsieh T, Lee J, Hsu C, Chiu C, et al. (2015) . J Agric Food Chem 63: 10388-10398.

, ,

8. Devassy J, Nwachukwu I, Jones PJ (2015) . Nutrit Rev 73: 155-165.

, ,

9. Subramaniam D, Ramalingam S, Houchen CW, Anant S (2010) . Mini Rev Med Chem 10: 359-371.

, ,

10. Osterman C, Gonda A, Stiff T, Moyron R, Wall N (2016) . Pancreas 45: 101- 109.

, ,